Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Summary
The purpose of this phase I trial is to study the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
General Information
NCT#: NCT03784677
Study ID: 2018-0680
Trial Phase: Phase I
Trial Sponsor: M.D. Anderson Cancer Center
Therapies Used in This Trial: SOR-C13